» Articles » PMID: 30921706

BAFF Promotes T Cell Activation Through the BAFF-BAFF-R-PI3K-Akt Signaling Pathway

Overview
Date 2019 Mar 29
PMID 30921706
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

B-cell activating factor from the tumor necrosis factor family (BAFF) has revealed its critical role in B cell proliferation and survival, as well as the pathogenesis of T-cell mediated autoimmune disease. However, the effect and molecular mechanisms of BAFF on T cell physiological function have not been fully elucidated. In this study it was seen that BAFF can promote the vitality of purified T cells, increase the proportion of CD3CD4, CD4CD25, CD4CD154, and CD4CD69 subgroups and reduce the proportion of CD4CD62L subgroups. Negating BAFF activity with Atacicept (TACI-Fc) reverses vitality and activation of T cells. Furthermore, immunofluorescence detection revealed that BAFF promotes the expression of BAFF receptor (BAFF-R) and transmembrane activator and CAML interactor (TACI) in T cells. Flow cytometry displayed that BAFF/BAFF-R activates the PI3K-Akt signaling pathway while the application of PI3K inhibitor (wortmannin) illuminated that BAFF induces T cell vitality and activation through the PI3K-Akt signaling pathway. We conclude that BAFF is involved in not only the physiology of B cells, but also that of T cells. BAFF affects physiological T-cell activation through BAFF-R-mediated activation of the PI3K-Akt signaling pathway which mirrors one of the pathological mechanisms of T cell-mediated autoimmune diseases.

Citing Articles

A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.

Davies R, Peng S, Lickliter J, McLendon K, Enstrom A, Chunyk A Clin Transl Sci. 2024; 17(11):e70055.

PMID: 39494621 PMC: 11532938. DOI: 10.1111/cts.70055.


BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses.

Lv Z, Wang T, Bi Y, Li D, Wu Q, Wang B Breast Cancer Res Treat. 2024; 209(2):405-418.

PMID: 39400783 DOI: 10.1007/s10549-024-07504-6.


Tumor necrosis factor superfamily signaling: life and death in cancer.

Ababneh O, Nishizaki D, Kato S, Kurzrock R Cancer Metastasis Rev. 2024; 43(4):1137-1163.

PMID: 39363128 PMC: 11554763. DOI: 10.1007/s10555-024-10206-6.


Causal relationship between immune cell phenotypes and risk of biliary tract cancer: evidence from Mendelian randomization analysis.

Hu Y, Wang K, Chen Y, Jin Y, Guo Q, Tang H Front Immunol. 2024; 15:1430551.

PMID: 39050844 PMC: 11266158. DOI: 10.3389/fimmu.2024.1430551.


[Research advances on B-cell activating factor and its targeted agents in inflammatory bowel disease].

Li L, Liu H, Wang L Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(3):315-320.

PMID: 38557386 PMC: 10986372. DOI: 10.7499/j.issn.1008-8830.2309126.